CC-90002

DRUG2 trials

Sponsors

Celgene

Conditions

Hematologic NeoplasmsLeukemia, Myeloid, AcuteMyelodysplastic Syndromes

Phase 1

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

CompletedNCT02367196

CelgeneHematologic Neoplasms

Start: 2015-03-12End: 2020-12-24Updated: 2021-08-12

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

TerminatedNCT02641002

CelgeneLeukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2016-03-01End: 2018-07-18Updated: 2018-10-18

Related Papers

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Annals of Hematology2022-01-0483 citations

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.

2021-07-1024 citations

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Blood2019-11-1348 citations

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood2019-11-1334 citations

Abstract 2009: CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is associated with an increase in M1-polarized macrophages

Cancer Research2017-07-013 citations